OncoTherapy Science's total inventories for the quarter that ended in Mar. 2026 was 円62.4 Mil. OncoTherapy Science's average total inventories from the quarter that ended in Sep. 2025 to the quarter that ended in Mar. 2026 was 円77.1 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. OncoTherapy Science's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was 円5.16.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
OncoTherapy Science's Days Inventory for the
six
months ended in Mar. 2026 was 35.93.
Inventory Turnover measures how fast the company turns over its inventory within a year.
OncoTherapy Science's Inventory Turnover for the quarter that ended in Mar. 2026 was 5.08.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
OncoTherapy Science's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.20.
OncoTherapy Science (TSE:4564) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
OncoTherapy Science's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
OncoTherapy Science's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
OncoTherapy Science Total Inventories Related Terms
OncoTherapy Science Total Inventories Historical Data
* Premium members only.
The historical data trend for OncoTherapy Science's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
OncoTherapy Science (TSE:4564) has a Total Inventories of 円62.4 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for OncoTherapy Science and its competitors.
Is OncoTherapy Science's Total Inventories too high?
OncoTherapy Science's current Total Inventories is 円62.4 Mil. Overall, OncoTherapy Science has a GF Score™ of 50/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Total Inventories compare to VRTX and REGN?
OncoTherapy Science's Total Inventories of 円62.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for OncoTherapy Science and its competitors. OncoTherapy Science's current Total Inventories is 円62.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円17.03, compared to a current price of 円21.00 — trading 23.3% above its estimated fair value. The current Total Inventories is 円62.4 Mil. OncoTherapy Science's overall GF Score™ is 50/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current Total Inventories is 円62.4 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (TSE:4564) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of 円21.00 is trading 23.3% above its estimated GF Value™ of 円17.03.
GuruFocus considers OncoTherapy Science to be Modestly Overvalued.
Key valuation signals for TSE:4564:
Total Inventories: 円62.4 Mil
GF Value™: 円17.03 vs. price of 円21.00 (23.3% above fair value)
No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
50GF Score
Get the complete analysis for TSE:4564
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4564 has been successfully added to your 
